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Abstract
Sulfamethoxazole/Trimethoprim (SMX/TMP) is a commonly used antibiotic, its' known adverse
reaction of hepatotoxicity leading to acute liver failure is considered rare. We present a case of a
22 year old female who developed jaundice and acute liver failure one week after taking SMX/TMP
for a UTI. After an extensive work up, a clinical diagnosis of SMX/TMP induced liver failure was
reached. Over the course of several weeks she made a good clinical and biochemical recovery with
supportive care. In this case report we describe her clinical presentation and course, and present
a brief review of the literature.
Introduction
Sulfamethoxazole/Trimethoprim (SMX/TMP) is a com-
monly used antibiotic for respiratory, gastrointestinal and
urinary tract infections caused by a range of aerobic gram-
positive and gram-negative bacteria. It also has activity
against Listeria monocytogenes, Nocardia and Pneuom-
cystis jiroveci.
SMX/TMP is generally well tolerated in non-HIV-infected
patients in whom adverse reactions occur in approxi-
mately 6 to 8 percent of individuals. In comparison, the
adverse reaction rate is as high as 25 to 50 percent in HIV-
infected patients, with many of the reactions being severe.
The most common adverse reactions include nausea,
vomiting, anorexia, dermatological reactions such as pru-
ritis, urticaria and less commonly Steven Johnson Syn-
drome. Life-threatening adverse reactions include
neutropenia, exfoliative dermatitis (a severe skin disorder
with generalized erythema and scaling) and toxic epider-
mal necrolysis (an acute severe reaction with widespread
erythema and detachment of the epidermis). Acute liver
failure has only been reported in a few cases worldwide,
and has been attributed to the sulphonamide component
of the drug.
Case presentation
A previously healthy 22 year old female presented to our
institution with nausea, vomiting and general malaise
which started 2 days after taking SMX/TMP for a presumed
urinary tract infection. Though feeling ill she continued
her antibiotic course. On day 6 of SMX/TMP, her family
noticed yellow discoloration of the sclera and urged her to
go to the hospital. SMX/TMP was stopped on admission.
On examination her only positive finding was generalized
icterus most notably in the sclera, she had no signs of
hepatic encephalopathy, or hepatomegaly. Her initial lab-
oratory investigations showed an AST of 3077, ALT 4067,
Alkaline Phosphatase 128, total bilirubin 5.1, INR 1.8,
and albumin of 3.6. Over the course of her hospital stay
her liver enzymes showed a downward trend, her total
bilirubin peaked at 24.4, with direct bilirubin of 17.5, and
Published: 18 July 2008
Cases Journal 2008, 1:44 doi:10.1186/1757-1626-1-44
Received: 18 June 2008
Accepted: 18 July 2008
This article is available from: http://www.casesjournal.com/content/1/1/44
© 2008 Abusin and Johnson; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cases Journal 2008, 1:44 http://www.casesjournal.com/content/1/1/44
Page 2 of 3
(page number not for citation purposes)
INR at 2.16, after which they all gradually dropped. Ultra-
sound Liver with Doppler Flow showed normal liver size
and echogenicity, with no obstruction of the biliary tree
and normal blood flow. She was found to be negative for
Hepatitis A, B, and C viruses, HIV, HSV and EBV. RPR,
autoimmune panel, thyroid function, serum copper and
ceruloplasmin were all within normal limits. Acetomi-
nophen was not detected in her blood. Based on the tim-
ing of jaundice in relation to SMX/TMP exposure, and the
absence of any other identifiable cause, she was diagnosed
with SMX/TMP induced acute liver failure. Her liver func-
tion improved with no intervention, and she made an
uneventful recovery. At 2 months, she was asymptomatic,
and her liver function tests including coagulation profile
were back to normal.
Discussion
The sulfamethoxazole component of SMX/TMP is respon-
sible for most of its' side effects including liver failure.
Although Trimethoprim alone can be used for treatment
of uncomplicated UTI[1], SMX/TMP is commonly used
for that purpose in the United States for unclear reasons.
Three forms of SMX/TMP induced liver damage have been
described; hepatocellular[2], mixed hepatocellular chole-
static[3], and (more recently) bile duct injury with ducto-
penia or Vanishing Bile duct syndrome[4,5]. The onset of
symptoms usually occurs within a few days of exposure as
did in our patient, but can take up to a 1–2 months[6,7].
Patients usually present with jaundice, nausea, vomiting,
and pruritis (if cholestatic). LFTs may show a hepatocellu-
lar or cholestatic pattern depending on the type of injury,
coagulopathy is also seen. Patients might have other fea-
ture of an allergic reaction such as skin rash, eosi-
nophilia[7,8]. Extrahepatic manifestations include
pancytopenia[8], pancreatitis[9,10], and acute renal fail-
ure[7,8].
Diagnosis is suspected from the clinical presentation, and
absence of other causes, in addition to suggestive changes
on liver biopsy. Invitro tests such as lymphocyte transfor-
mation test have been reported to aid in the diagno-
sis[11]. Rechallenge with SMX/TMP as a method for
diagnosis has been reported in the literature in the
1960s[12,13]. However, rechallenge even at small doses
can lead to terminal hepatic failure[2], and it has fallen
out of favor and only reported inadvertently since[14].
The severity of SMX/TMP induced liver injury can range
from mild symptoms with elevated liver enzymes to ful-
minant hepatic failure with hepatic encephalopathy and
coagulopathy. Outcome can be favorable with spontane-
ous resolution, as in our patient, or unfavorable leading to
death reported in both HIV[15], (in this case it was asso-
ciated with a delayed diagnosis) and non HIV infected
patients[2,16].
Treatment is generally supportive, liver transplantation
has been successful for both fulminant hepatic failure[17]
and vanishing bile duct syndrome[4].
Conclusion
This case illustrates a rare but clinically important side
effect of a commonly used antibiotic. It alerts the physi-
cian to suspect drugs as a cause in any patient presenting
with jaundice and/or acute liver failure. Failure to do so
has been associated with a fatal outcome. It also shows
that in the right clinical context, the diagnosis can be
established without the need for an invasive liver biopsy
in a patient with coagulopathy.
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